Journal of Clinical Oncology
Articles in this Issue
Phase II study evaluating olutasidenib in patients with <i>IDH1</i> -mutated clonal cytopenia of undetermined significance or lower-risk myelodysplastic syndromes/chronic myelomonocytic leukemia.
TPS6585 Background: Observational studies have demonstrated that individuals with clonal cytopenia of undetermined significance (CCUS) involving high-risk...
Polygenic risk score for breast cancer in the Thai population: Addressing genetic disparities in underrepresented populations.
10572 Background: Effective breast cancer prevention and management require accurate risk prediction tools. Polygenic risk scores (PRS) have shown promise...
Assessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting.
e23003 Background: Patient withdrawal in oncology clinical trials ranges from 5% to 45%, posing significant threats to trial integrity. High attrition rat...
Trends and persistent disparities in incidence, mortality, and survival of pancreatic cancer: A Surveillance, Epidemiology, and End Results program–based retrospective cohort study (2000–2021).
e16360 Background: Pancreatic cancer remains a highly lethal malignancy with increasing incidence and mortality, compounded by significant survival dispar...
Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL).
e13741 Background: The NCCN guidelines for first-line (1L) regimens in CLL have evolved over the past decade, shifting from ibrutinib (ibr) and chemoimmun...
Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.
11516 Background: Gamma secretase inhibitors (GSIs) have shown antitumor activity against desmoid tumors (DT). The RINGSIDE Phase 2 study (NCT04871282) de...
National cancer system characteristics and global pan-cancer outcomes.
1625 Background: Approximately 29.9 million cancer cases and 15.3 million deaths are anticipated by 2040 globally. Health systems must invest in cancer sy...
Thrombotic events and mortality associated with bispecific antibodies in lung cancer: A systematic review.
e15101 Background: Bispecific antibodies have emerged as a promising therapeutic option in lung cancer. Despite their therapeutic potential, concerns abou...
Productivity of National Cancer Institute K Awardees and their transition to independent funding.
9010 Background: The National Cancer Institute (NCI) mentored career development (K) awards program plays an essential role in supporting early-career sci...
Predictive biomarkers for immune-related adverse events: PD-L1% and somatic mutations.
e14649 Background: Immune checkpoint inhibitors (ICIs) with anti-PD-L1 activity are a mainstay of therapy in the treatment of non-small cell lung cancer (...
Impact of tumor burden on outcomes after immune versus conventional therapies.
e20621 Background: Tumor burden has been previously suggested to be an important determinant of immunotherapy efficacy due to tumor bulk impeding lymphocy...
Clinico-genomic characterization of <i>PALB2</i> -mutated pancreatic adenocarcinoma.
4169 Background: Pancreatic adenocarcinoma (PDAC) with germline (g) or somatic (s) mutations in BRCA1/2 and PALB2...
Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.
7526 Background: IV isatuximab (Isa) can provide benefit to patients (pts) in multiple combinations across the therapeutic spectrum for MM. SC administrat...
Systematic communication model to facilitate conversations about metastatic breast cancer.
11141 Background: For patients with metastatic breast cancer (mBC) understanding their stage and treatment goals is essential to engage in shared decision...
Landscape of genomic alterations in genes implicated in the regulation of hypoxia inducible factor (HIF) signaling: A pooled analysis of two pan-cancer cohorts.
3143 Background: HIF2 alpha inhibitors (HIF2i) have been recently approved for VHL-related tumors, especially clear cell renal cell carcinoma (ccRCC). Alt...
Chemoinduction therapy and its response in Jehovah’s Witnesses with acute lymphoblastic leukemia: A systematic review.
e18543 Background: The refusal of Jehovah's Witnesses to accept blood and blood product transfusions proves to be a significant clinical challenge in acut...
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with <i>EGFR</i> mutations: Heat on Beat randomized phase II study.
8633 Background: Osimertinib (Osi) has been established as a standard of care for patients (pts) with EGFR -mutant advanced non-sm...
Impact of pressure-related injury on hospitalized patients with colorectal cancer: A United States population-based cohort study.
e15688 Background: Colorectal cancer is the third most common cancer worldwide. Newer treatment options have significantly helped improve quality of life,...
EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.
TPS4221 Background: Locoregional therapy, such as transarterial chemoembolization (TACE) or TARE, is commonly used to treat uHCC eligible for embolization...
Effects of nuclear CD276 on CD36-mediated lipid metabolism reprogramming on TKI resistance in hepatoma..
e16174 Background: The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited...
Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial).
3119 Background: BRAF is a frequently mutated gene in cancer, with most mutations (mut) at the activating hotspot V600 codon. Recently, kinase...
A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors.
6102 Background: Alrizomadlin, an investigational MDM2 inhibitor, has shown a manageable safety profile with preliminary efficacy in liposarcoma (LPS) and...
Efficacy and safety of mesenchymal stem cell therapy in radiation induced xerostomia in patients with head and neck carcinoma: A systematic review and meta analysis of randomized controlled trials.
e18015 Background: Radiation-induced xerostomia, a common complication of head and neck radiotherapy, severely impacts quality of life by reducing salivar...
First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
TPS6581 Background: Acute myeloid leukemia (AML) is the most common adult acute leukemia. Patients with relapsed or refractory (R/R) disease have dismal o...
Area deprivation index and EGFR-mutated non-small-cell lung cancer.
8595 Background: Survival outcomes in patients with non-small-cell lung cancer (NSCLC) have improved in recent decades with availability of immunotherapy...